NCT05859776View on ClinicalTrials.gov

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 19, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

May 31, 2025

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

AXT107 Low Dose

Single suprachoroidal injection of AXT107 (0.125 mg/eye)

DRUG

AXT107 Mid Dose

Single suprachoroidal injection of AXT107 (0.250 mg/eye)

DRUG

AXT107 High Dose

Single suprachoroidal injection of AXT107 (0.500 mg/eye)

Trial Locations (4)

16507

Erie Retina Research, Erie

28803

Asheville Eye Associates, Asheville

63128

The Retina Institue, St Louis

01107

New England Retina Consultants, Springfield

Sponsors
All Listed Sponsors
lead

AsclepiX Therapeutics, Inc.

INDUSTRY

NCT05859776 - Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) | Biotech Hunter | Biotech Hunter